 |
| |
IN THIS ISSUE |
|
|
Dawn AC 16th User Group
North American User Group
Dawn AC 20th Benchmarking Run
Book Printer Reminder
New Blood Clot Drug Launched
Heparin Injection Impurity Alerts
|
 |
|
Welcome to the April edition
of the
DAWN AC Anticoagulation Software E-Newsletter for 2008.
|
|
Dawn AC Anticoagulation
Software 16th User Group 2008 |
|
We are holding our annual Dawn AC User Group on
the 29th and 30th of September this year at the Rheged Centre.
The User Group, as
many of you know, offers the chance for Health Care
Professionals to share ideas and learn alternative methods of
best practice within Anticoagulation therapy, as well as the
day being informative and beneficial.
We are keen to hear from those of you who would
like to give a short talk at the User Group Meeting, we are
offering a ‘speaker’s package’ where there will be a
£100 reduction in the meeting
fee and we also help with your presentation
preparation. In response to user requests, we invite you to
share how you use Dawn AC in different settings eg laboratory
based, community based with POC, pharmacist managed. In
addition, we would be interested in your experiences with
Version 7. If you are interested in speaking at our user group
then please contact us at
sales@4s-dawn.com.
|
North American User Group |
|
The North American User Group is
going to be held on the 10th October in Albuquerque, the day
before the South West Symposium on Thrombosis and Hemostasis,
also being held in Albuquerque, making this, potentially, a
very
informative and worthwhile trip.
We are, however, in need of
speakers to contribute to the success of the day. If anyone
would be interested in giving a short presentation, rather
like what is mentioned above, then again we would be keen to
hear from you.
Thank you to everyone who kindly
offered to help organise this years meeting. As the
meeting this year is to be held in Albuquerque to gain the
benefit of two meetings in one trip, the following people from
around this area are organising the event:
- Rudy Pena, ABQ Health
Partners, Albuquerque
- Dan Witt, Kaiser Permanente, Colorado Region
- Angela Aldrich, Presbyterian
Hospital, Albuquerque
|
|
Dawn AC 20th Benchmarking Run |
|
 For
our benchmarking participants, please stand by
for the data collection for the next
run of the benchmarking
service. Participants should also have received an email with an
invitation to complete a benchmarking satisfaction survey.
Responses to our survey are very much appreciated. If you have not
received this email and would like to complete the survey then
please email
louise@4s-dawn.com.
Reminder for all 'yellow book' printer
users:
If you change your computer or have it
reconfigured in any way, say with other new
software/hardware, please remember to ensure that the
printer driver is configured to print directly
to the printer instead of spooling print jobs for safe
operation of the book printer. This prevents the wrong
instruction from previous patients being printed if the operator
does not work rigorously with the barcode reader checks. If any
help is required with the set up or support of your book
printer, then please contact the Dawn AC support desk for
assistance.
|
New Blood Clot Drug Launched |
|
A new blood-thinning drug, Praxada, has been launched recently and
makers hope that this will prevent many deaths each year resulting
from fatal blood clots.
Praxada will initially be used on patients after knee and hip
replacement surgery, and is the first daily tablet to be
introduced for high risk patients in danger of clotting since
warfarin.
The drug is to be taken once a day after surgery. A cardiac nurse
at the British Heart Foundation, Judy O'Sullivan, commented, "A
safe and effective anti-clotting medicine that does not require
regular monitoring will provide a significant step forward in
improving care for patients at high risk of developing a blood
clot".
To read more of this article, please follow the link below:
|
|
Heparin Injection Impurity Alerts
|
|
The Medicines and Healthcare Products Regulatory Agency said
recently that some enoxaparin (Clexane) batches contain low
levels of impurity (named over-sulphated chondroitin
sulphate), and are warning nurses to keep a close eye on
patients for any signs of adverse drug reactions.
The agency did say that there was no evidence that this is
linked to a risk in patients, and so healthcare professionals
are advised to keep administering the drug as normal.
The UK has not presently seen an increase in adverse drug
reactions, unlike 11 other countries around the world using
other heparin products, and so nurses are being advised to
monitor patients closely.
To read more of this article, please follow the link below:
|
|
